Comprehensive genomic profiling of clinically relevant cancer biomarkers
GALEASTM Tumor
Enhanced comprehensive genomic profiling (CGP) of clinically relevant biomarkers at your fingertips
Expertly curated content delivered through a single workflow for CGP
GALEAS Tumor is an expertly curated NGS panel developed in parallel with bioinformatics pipelines for the comprehensive profiling of solid tumors. It targets 519 carefully selected, clinically relevant genes aligned with the UK NHS national genomic test directory, NCCN, FDA and ESMO guidelines.
The comprehensive design supports stratification of both common and rare cancers in a single workflow and enables confident detection of a wide range of gene aberrations known to drive cancer including SNVs, INDELs, selected fusions and genome-wide CNVs.
Probe enhancements support the assessment of other biomarkers like Tumor Mutational Burden (TMB), Microsatellite Instability (MSI) and Homologous Recombination Deficiency (HRD).
Key Features
- Targets 519 genes covering rare and common cancers including hereditary and pediatric cancers.
- Genome-wide SNP backbone delivers robust and reliable CNV calling.
- Probes enhancements allow MSI and TMB Immuno-oncology biomarker scoring.
- BRCA variant calling and GI scoring deliver HRD assessment in a single workflow.
- Enhanced coverage of the 1p/19q co-deletion associated with Glioma supports brain cancer studies.
- Coverage of 10 Fusion/Structural rearrangements: ALK, BRAF, EGFR, FGFR2, FGFR3, NTRK1, NTRK2, RET, ROS1, TMPRSS2 reduces need for additional workflows.
- Sample identity tracking SNPs reduce potential errors in laboratory processes.
- Target 64 Pharmacogenomics (oncology) markers.
- Incorporates HLA design relevant for solid tumors.
Performance
Delivering clinical precision for SNVs and INDELS:
GALEAS Tumor confidently identifies somatic variants with 100% recall and precision
GALEAS Tumor confidently identified somatic variants in a colorectal cancer (CRC) cohort with 100% recall and precision (Figure 1).
The efficacy of the GALEAS Tumor workflow was assessed using reference material from FFPE containing 23 SNVs and INDELs that had previously been confirmed by ddPCR.
A strong correlation between NGS and ddPCR- determined VAFs was observed with a mean depth of 500x (R2 = 0.99) (Figure 2).
Unveiling copy number insights:
GALEAS Tumor delivers precision CNV detection
The design of GALEAS Tumor incorporates a copy number backbone targeting informative genome wide SNPs enabling enhanced CNV calling.
Strong correlation of GALEAS Tumor SNP backbone data with shallow whole genome sequencing (sWGS) demonstrates its efficacy as a reliable tool for comprehensive CNV analysis in clinical genomic profiling (Figure 3).
Samples with known copy number variations in EGFR and MET were assessed using GALEAS Tumor at 3, 6 and 12 copies. They were quantitatively confirmed by GALEAS Tumor. (Figure 4).
Empowering access to immunotherapy treatment:
GALEAS Tumor delivers a combined tumor genomic instability measurement for TMB and MSI
GALEAS Tumor demonstrates excellent utility as a solution for the determination of MSI scoring and TMB status, offering insights into these immuno-oncology biomarkers.
GALEAS Tumor correctly identified 100% of MSS (microsatellite stable) and normal samples, and 23/24 MSI-H (microsatellite instability-high) in 50 colorectal cancer (CRC) samples evaluated (Figure 5).
TMB is a key immuno-oncology biomarker across multiple cancer types and has been shown to correlate strongly with MSI status in colorectal cancer. 1, 2 A strong correlation was observed between the GALEAS Tumor derived TMB scores for a CRC cohort (Median TMB 28.24, log2 TMB 1.45) and corresponding sample MSI status (Figure 6).
Streamlining HRD assessment:
GALEAS Tumor delivers a single workflow for HRD assessment removing the need for separate BRCA and genomic instability testing.
Shown to deliver high concordance with orthogonal data, GALEAS Tumor offers laboratories a streamlined and efficient way of incorporating HRD scoring into their comprehensive profiling workflow. HRD status is determined by combining a genomic instability score with a pathogenic BRCA mutation. Performance was tested using 265 samples, including 162 Ovarian Cancer samples with orthogonal HRD status, HRD high, low and HRP reference standards (3), NOCANCER FFPE tissue (50) and a cohort of colorectal cancer samples (50) (CRC) The latter two cohorts were expected to be HRD low. The concordance between the GALEAS Tumor HRD status and the orthogonal HRD status is shown in Figure 7.
Why choose GALEAS Tumor?
Current and clinically relevant content
Detect SNVs, INDELs, selected fusions, CNVs, TMB, MSI and HRD associated with a wide range of cancers from common to rare in a single workflow.
Highly efficient capture chemistry
High on-target rates and excellent uniformity of coverage deliver more efficient sequencing and better sensitivity for comprehensive genomic profiling.
Supported by GALEAS software
Developed in parallel with the GALEAS Tumor panel, our GALEAS analysis software provides users with optimised bioinformatics for accurate variant calling and supports rapid integration into routine use.
*For Research Use Only. Not for use in diagnostic procedures.
The GALEAS Tumor workflow is simple and easy
gDNA, FFPE DNA samples
Wide range of sample types including FFPE, frozen tissue and blood
Sample preparation
DNA extraction kits
Prepare libraries and enrich
GALEAS Tumor
Sequence
Illumina NGS Sequencing System
Call variants
GALEAS analysis software
Report
Generate reports for HRD, TMB and MSI
Interpret and report
Utilize third party tertiary software for interpretation and reporting
Optimised Library Preparation
GALEAS Tumor library preparation is simple and easy compared to other targeted sequencing methods for hybridization and capture.
It requires as little as 10 ng of DNA and takes less than 10 hours, with less than two hours hands-on time. It is designed with multiple stop points to provide flexibility within laboratory processing. Library preparation can be run manually or automated (up to 96 samples in a single batch). Indexes are available for up to 384 samples to facilitate high throughput laboratories and to allow for flexible batch sizes.
Turnkey bioinformatics
Complimentary access to GALEAS cloud-based software delivers high quality variant calling and genome wide scores
Cutting-edge bioinformatics pipelines were developed in tandem with, and specifically for GALEAS Tumor ensuring superior detection of all key variant types (SNV, INDEL, CNV and SV’s) as well as genome wide scores for MSI and TMB and assessment of HRD. This turn-key software solution requires no specialist bioinformatic knowledge, enabling labs to rapidly integrate GALEAS Tumor into routine use.
Including pre-validated, optimised variant calling software with GALEAS Tumor gives clinical scientists confidence that they can deliver the robust, reliable and clinically actionable information that is critical for downstream interpretation.
Technical performance
High on-target rates and excellent uniformity of coverage deliver more efficient sequencing for comprehensive genomic profiling
GALEAS Tumor uses the Cell3 Target library preparation technology optimised by Nonacus to deliver a high percentage of on-target reads, low duplication rates and more uniform coverage.
This exceptional technical performance means lower DNA inputs, less sequencing and higher recall and precision across more variants.
| Key quality indicator | GALEAS Tumor |
|---|---|
| Number of genes | 519 |
| Capture Panel Size (Mb) | 3.74 Mb |
| Gb required for mean 500x coverage (2x100bp PE) | 5 Gb |
| Percentage coverage ≥250x | 98% |
| Percentage on or near bait | 71% |
| Percent duplication | 9% |
| SNV recall | 100% |
| INDEL recall | 100% |
See our customer publications
| Product Name | Catalogue No. |
| GALEAS Tumor Kit Frag A (96 samples) | NGS_GAL_TCP_FR_96_A |
| GALEAS Tumor Kit Frag B (96 samples) | NGS_GAL_TCP_FR_96_B |
| GALEAS Tumor Kit Frag C (96 samples) | NGS_GAL_TCP_FR_96_C |
| GALEAS Tumor Kit Frag D (96 samples) | NGS_GAL_TCP_FR_96_D |
| GALEAS Tumor Kit Frag (16 samples) | NGS_GAL_TCP_FR_16 |
Which clinical guidelines does GALEAS Tumor cover?
Clinically relevant content is aligned with the UK NHS national genomic test directory, NCCN, FDA and ESMO guidelines.
What coverage does the panel have for BRCA1 and BRCA2?
Full coding exon coverage.
Can you sequence GALEAS Tumor libraries on Illumina sequencers?
GALEAS Tumor is compatible with all Illumina Sequencers. For solid tumor samples, to obtain optimal results and be able to detect variants down to an expected 1% Variant Allele Frequency (VAF) at 500x average depth of coverage, it is recommended that each sample be sequenced to achieve 5 Gb of data, or 25 million reads using 2×100 bp paired end sequencing. On this basis, select the Illumina platform and flow cell that will enable desired throughput at these conditions.
Can I detect fusions other than those stated in your literature?
There is potential to detect fusions from any capture region in the panel, not just the key fusions stated in literature.
Can I automate the GALEAS Tumor workflow?
Hamilton platforms will initially support automation, but we would be happy to work with customers directly to support specific needs for a certain platform. If you are interested in automating this workflow, contact your account manager.
